Shih Lin Goh

merck & company usa

H指数:22

被引数:2,194

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

VIRUSES-BASEL

IF3.5

2024-07-180

OAAI

Alvarez, Nadine; Adam, Gregory C.; Howe, John A.; Sharma, Vijeta; Zimmerman, Matthew D.; Dolgov, Enriko; Rasheed, Risha; Nizar, Fatima; Sahay, Khushboo; Nelson, Andrew M.; Park, Steven; Zhou, Xiaoyan; Burlein, Christine; Fay, John F.; Iwamoto, Daniel V.; Bahnck-Teets, Carolyn M.; Getty, Krista L.; Lin Goh, Shih; Salhab, Imad; Smith, Keith; Boyce, Christopher W.; Cabalu, Tamara D.; Murgolo, Nicholas; Fox, Nicholas G.; Mayhood, Todd W.; Shurtleff, Valerie W.; Layton, Mark E.; Parish, Craig A.; McCauley, John A.; Olsen, David B.; Perlin, David S.

No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-07-095

OAAI

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-02-164

PRE

Shurtleff, Valerie W.; Layton, Mark E.; Parish, Craig A.; Perkins, James J.; Schreier, John D.; Wang, Yunyi; Adam, Gregory C.; Alvarez, Nadine; Bahmanjah, Soheila; Bahnck-Teets, Carolyn M.; Boyce, Christopher W.; Burlein, Christine; Cabalu, Tamara D.; Campbell, Brian T.; Carroll, Steven S.; Chang, Wonsuk; de Lera Ruiz, Manuel; Dolgov, Enriko; Fay, John F.; Fox, Nicholas G.; Goh, Shih Lin; Hartingh, Timothy J.; Hurzy, Danielle M.; Kelly III, Michael J.; Klein, Daniel J.; Klingler, Franca-Maria; Krishnamurthy, Harini; Kudalkar, Shalley; Mayhood, Todd W.; McKenna, Philip M.; Murray, Edward M.; Nahas, Debbie; Nawrat, Christopher C.; Park, Steven; Qian, Dongming; Roecker, Anthony J.; Sharma, Vijeta; Shipe, William D.; Su, Jing; Taggart, Robert V.; Truong, Quang; Wu, Yin; Zhou, Xiaoyan; Zhuang, Ningning; Perlin, David S.; Olsen, David B.; Howe, John A.; McCauley, John A.

Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-01-1013

OAAI

The HIV-1 capsid core is an opportunistic nuclear import receptor

NATURE COMMUNICATIONS

IF15.7

2023-06-2418

OAAI

Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2023-02-2211

PRE

A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells

ACS CHEMICAL BIOLOGY

IF3.8

2022-08-3118

PRE

Moore, Keith P.; Schwaid, Adam G.; Tudor, Matthew; Park, Sangho; Beshore, Douglas C.; Converso, Antonella; Shipe, William D.; Anand, Rajan; Lan, Ping; Moningka, Remond; Rothman, Deborah M.; Sun, Wanying; Chi, An; Cornella-Taracido, Ivan; Adam, Gregory C.; Bahnck-Teets, Carolyn; Carroll, Steven S.; Fay, John F.; Goh, Shih Lin; Lusen, Jeffrey; Quan, Shuo; Rodriguez, Silveria; Xu, Min; Andrews, Christine L.; Song, Cheng; Filzen, Tracey; Li, Jing; Hollenstein, Kaspar; Klein, Daniel J.; Lammens, Alfred; Lim, U-Ming; Fang, Zhiyu; McHale, Carolyn; Li, Yuan; Lu, Meiqing; Diamond, Tracy L.; Howell, Bonnie J.; Zuck, Paul; Balibar, Carl J.

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2022-06-2122